Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 3/20 | 0.35 |
| ▸ | MET | P08581 | 4/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029520 | 0.89 | ALDH1A1 (0.41) | ALDH1A1TDP1CYP3A4TSHRHSD17B10 | |
| SCHEMBL2029811 | 0.86 | ALDH1A1 (0.42) | ALDH1A1TDP1CYP3A4TSHRHSD17B10 | |
| SCHEMBL2030686 | 0.82 | ALDH1A1 (0.40) | ALDH1A1TDP1CYP3A4TSHRHSD17B10 | |
| SCHEMBL2032496 | 0.79 | CHEK1 (0.41) | ALDH1A1TDP1CYP3A4LMNAL3MBTL1 | |
| SCHEMBL2030322 | 0.73 | ALDH1A1 (0.49) | ALDH1A1TDP1TSHRHSD17B10LMNA | |
| SCHEMBL13523944 | 0.69 | ALDH1A1 (0.53) | ALDH1A1TDP1CYP3A4TSHRHSD17B10 | |
| SCHEMBL8136159 | 0.68 | ALDH1A1 (0.57) | ALDH1A1TDP1CYP3A4TSHRHSD17B10 | |
| SCHEMBL31363823 | 0.68 | ALDH1A1 (0.57) | ALDH1A1TDP1CYP3A4TSHRHSD17B10 | |
| SCHEMBL1143325 | 0.68 | ALDH1A1 (0.57) | ALDH1A1TDP1CYP3A4TSHRHSD17B10 | |
| SCHEMBL11762482 | 0.68 | LMNA (0.36) | ALDH1A1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096624-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-8399433-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| EP-2438056-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2010141406-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | ALDH1A1 1117/4885TDP1 472/4885CYP3A4 3332/4885 |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | ALDH1A1 1117/4885TDP1 472/4885CYP3A4 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.